Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GALECTIN THERAPEUTICS INC.

(GALT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Galectin Therapeutics Inc.
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The CompanyÔÇÖs product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The CompanyÔÇÖs lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.

Number of employees : 6 people.
Managers
Name Title Age Since
Joel Lewis President, Chief Executive Officer & Director 51 2020
Jack W. Callicutt Chief Financial Officer & Secretary 53 2018
Pol F. Boudes, Dr. Chief Medical Officer 64 2020
Ezra R. lowe, Dr. Executive Director-Clinical - -
Marla Mills-Wilson Executive Director-Clinical Operations - -
Gilbert Frank Amelio, Dr. Independent Director 77 2009
Kevin D. Freeman Vice Chairman 59 2018
Marc Rubin, Dr. Independent Director 66 2011
Gil S. Omenn, Dr. Independent Director 79 2014
Richard E. Uihlein Chairman 75 2018
Members of the board
Name Title Age Since
Richard E. Uihlein Chairman 75 2018
Gilbert Frank Amelio, Dr. Independent Director 77 2009
James C. Czirr Director 67 -
Kevin D. Freeman Vice Chairman 59 2018
Marc Rubin, Dr. Independent Director 66 2011
Harold H. Shlevin, Dr. Director 71 2020
Gil S. Omenn, Dr. Independent Director 79 2014
Joel Lewis President, Chief Executive Officer & Director 51 2020
Kary Noel Eldred Independent Director 46 2018
Richard A. Zordani Independent Director 48 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 59,341,305 42,756,912 72.1% 0 0.0% 70.5%
Stock B 0 176 0 0.0% 0 0.0%
Stock C 0 1,302,500 0 0.0% 0 0.0%
Shareholders
NameEquities%
Richard E. Uihlein 7,930,393 13.4%
10X Capital Management LLC 6,188,940 10.4%
The Vanguard Group, Inc. 1,925,473 3.24%
SagePoint Financial, Inc. (Investment Management) 1,260,852 2.12%
James C. Czirr 770,616 1.30%
Catalyst Capital Advisors LLC 675,000 1.14%
Kevin D. Freeman 660,180 1.11%
BlackRock Fund Advisors 656,364 1.11%
Geode Capital Management LLC 540,866 0.91%
Geneos Wealth Management, Inc. 491,367 0.83%
Company contact information
Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard
Suite 240
Norcross, GA 30071

Phone : +1.678.620.3186
Fax : +1.770.864.1327
Web : http://www.galectintherapeutics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Galectin Therapeutics Inc.